Drug profile

The FDA adverse-event record for Afoxolaner, Moxidectin, And Pyrantel

29 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Afoxolaner, Moxidectin, And Pyrantel. Species, reactions, and outcomes follow.

#1464 of 2,679
by report volume (all drugs)
29
adverse-event reports
6.9%
death-coded share
Dog
most-reported species

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Afoxolaner, Moxidectin, And Pyrantel ranks #1463 of 2679 by total reports (29). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1463
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Afoxolaner, Moxidectin, And Pyrantel has 29 reports now versus 25 in that prior snapshot: 4 more (16.0%).

Report change
+4
Death-coded reports
+0
Death-coded share
−1.1 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Afoxolaner, Moxidectin, And Pyrantel changes

Signature read: death-coded report count at 2 is the most distinctive stamp on Afoxolaner, Moxidectin, And Pyrantel's FDA AER row.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
29
Total Reports
2
Deaths Reported
6.9%
Death-coded share of reports

Active Ingredients

Afoxolaner, Moxidectin, And Pyrantel

Administration Routes

OralUnknown

Species Affected

Dog 29

Most Affected Breeds

Retriever - Labrador 4
Beagle 3
Terrier - Bull - American Pit 3
Lhasa Apso 2
Shepherd Dog - German 2
Dog (unknown) 1
Greater Swiss Mountain Dog 1
Retriever (unspecified) 1
Boxer (German Boxer) 1
Cattle Dog (unspecified) 1

Most Reported Reactions

Lack of efficacy (endoparasite) - heartworm 6
Abnormal radiograph finding 4
Diarrhoea 3
Decreased haemoglobin 3
Neutropenia 3
Eosinopenia 3
Leucopenia NOS 3
Deafness 3
Vomiting 2
Hypersalivation 2
Collapse NOS (see also Cardio-vascular and Neurological disorders) 2
Tense abdomen 2

Outcome Breakdown

Ongoing
16 (55.2%)
Outcome Unknown
5 (17.2%)
Recovered/Normal
3 (10.3%)
Recovered with Sequela
3 (10.3%)
Died
2 (6.9%)

Afoxolaner, Moxidectin, And Pyrantel Adverse Event Insights

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Afoxolaner, Moxidectin, And Pyrantel (#1464 of 2,679 by report volume); death-coded 6.9%. PlainBreed drug row · death-coded report count stamp 2 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →